Ourdisease of interest is Diabetes 2, which is a chronic condition that affectsthe way the body processes blood sugar. Type 2 diabetes is a complex metabolicdisorder, which is developed from decreasing pancreatic insulin secretion andother factors contributing to decreasing of insulin action or insulinresistance. As the disease advances, the production of insulin is slowlydiminished, leading to dynamic stages of hyperglycemia and as the secretion ofinsulin is decreased, the blood level of glucose is increased. Accordingto the WHO 9% of the world had diabetes in 2014, of which 90% of them sufferedfrom type 2 diabetes. The International Diabetes Federation suggest that everyyear 5 million deaths are linked to diabetes, making it more than the burden ofHIV/AIDS, tuberculosis and malaria combined. Therehas been an increase in the number of oral antihyperglycemic drug classes, eachwith a particular mechanism of action.
They have shown to be fairly equal andeffective in lowering the patients blood glucose concentrations. With more drugchoices comes more difficult decision making for physicians and patients, sinceeach of the drug classes have a particular adverse effect. Currentlythere are five oral drug classes that are available for the treatment of type 2diabetes. These include Sulfonylurea (SU) drugs, Biguanides, Alpha-GlucosidaseInhibitors, Thiazolidinediones and Non-SU Secretagogues. Out of all the drugson the market right now metformin has become the most prescribed singleantihyperglycemic drug and that’s mostly because of its association with weightloss. Thechoice of drug for the patient must be chosen based on different clinicalfactors and the particular patients characteristics. By comparing thesociodemographic and clinical characteristics of type 2 diabetic patients thatare on antihyperglycemic treatment and those that are not, we will be able to bettermanage the treatment of type 2 diabetic patients.